Patent ID: 8999383
Filing Date: 2015-04-07
Classification: A61K,A61P,C07K

Abstract:
1. A solid oral dosage form comprising a therapeutically effective amount of one or more GnRH antagonists selected from the group consisting of acyline, abarelix, cetrorelix, degarelix, ganirelix, and a pharmaceutically acceptable salt thereof, and a sufficient amount of at least one anti-gelling agent to reduce the gelation of the GnRH antagonist, wherein at least one anti-gelling agent is a medium chain fatty acid salt and has a carbon chain length of from about 8 to about 14 carbon atoms; wherein the solid oral dosage form is prepared by mixing the one or more GnRH antagonists with the at least one anti-gelling agent; wherein the final step of the preparation of the GnRH antagonist is conducted in the presence of a co-solvent system in a manner such that the gelation of the GnRH antagonist is reduced, wherein the co-solvent system comprises water and at least one water-miscible solvent selected from the group consisting of methanol, ethanol, iso-propanol, tert-butanol, acetonitrile and methylene chloride.